Company intelligence / Profile preview

KinoPharma, Inc.

Ownership: Private
Development stage: Phase 2

Overview

KinoPharma is a clinical-stage biopharmaceutical company developing first-in-class small molecule drugs for diseases with high unmet medical need. Its lead program targets persistent HPV infections that cause cervical intraepithelial neoplasia and cervical cancer. The company has initiated clinical trials in multiple countries and collaborates closely with Kyoto University. Other pipeline assets target warts, epidemic keratoconjunctivitis, Down syndrome, and Alzheimer’s disease. Lead programs have reached Phase 2 clinical trials.

Therapeutic areas: OphthalmologyDermatologyOncologyRare DiseasesNeurology
Modalities: Small moleculesChemical drugs
Industry: Biotech

Drug pipeline

9 assets

KNP-2002

8 more assets in the full pipeline.

Partnerships

Close academic collaboration with Kyoto University for research and development activities.

Beyond the preview

Go deeper on KinoPharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KinoPharma, Inc..